How effective are topical calcineurin inhibitors for morphea?

Morphea, also called localised scleroderma, can begin with inflammation and later produce firm, tight or discoloured skin. A topical calcineurin inhibitor works at the skin surface by moderating immune signals, so its potential benefit is greatest when activity is superficial and accessible to a cream or ointment. It does not replace assessment of depth, movement across a joint, facial involvement or signs that the disease is progressing. A quiet-looking pale or brown area may represent an old change rather than active inflammation, and the treatment decision depends on that distinction.

Use the medicine exactly as prescribed and keep scheduled reviews, even if the patch feels stable. Mark or photograph the edge in consistent lighting to help identify spread, while remembering that colour can vary with tanning and lighting. Moisturise tight skin and maintain comfortable movement as advised; do not massage aggressively or use heat-based devices over an active or uncertain lesion. Tell the clinician about numbness, weakness, restricted movement, new lesions or involvement of the scalp, face or genital area. These details can change the treatment approach.

Seek earlier dermatology review if a patch enlarges, becomes harder or more painful, crosses a joint, causes restricted movement, or develops a deep groove or ulcer. New facial changes, scalp involvement with hair loss, or symptoms near the eye deserve prompt assessment. Contact the prescriber if application causes severe burning, swelling, blistering or crusting. Rapid progression or functional change should not be managed by simply applying more product.

Ask whether the morphea is active and superficial, how depth will be monitored, what signs would indicate escalation, and whether movement or specialist assessment is needed. Clarify the review interval, skin-care routine and how to distinguish treatment irritation from disease activity.